Abstract

BackgroundChronic hepatitis B virus (HBV) infection is the leading cause of hepatocellular carcinoma (HCC) world-wide. HBV variants, particularly the G1896A pre-core (PC) and A1762T/G1764A basal core promoter (BCP) mutations, are established risk factors for cirrhosis and HCC, but the molecular biological basis is unclear. We hypothesized that these variants result in differential HBV replication, APOBEC3 family expression, and cytokine/chemokine expression.MethodsHepG2 cells were transfected with monomeric full-length containing wild-type, PC, or BCP HBV. Cells and supernatant were collected to analyze viral infection markers (i.e., HBsAg, HBeAg, HBV DNA, and RNA). Cellular APOBEC3 expression and activity was assessed by quantitative real-time (qRT)-PCR, immunoblot, differential DNA denaturation PCR, and sequencing. Cytokine/chemokines in the supernatant and in serum from 11 CHB carriers (4 non-cirrhotic; 7 cirrhotic and/or HCC) with predominantly wild-type, PC, or BCP variants were evaluated by Luminex.ResultsHBeAg expression was reduced in PC and BCP variants, and higher supernatant HBV DNA and HBV RNA levels were found with A1762T/G1764A vs. G1896A mutant (p < 0.05). Increased APOBEC3G protein levels in wild-type vs. mutant were not associated with HBV covalently closed circular DNA G-to-A hypermutations. Differences in cytokine/chemokine expression in culture supernatants, especially IL-13 were observed amongst the variants analyzed. Noticeable increases of numerous cytokines/chemokines, including IL-4 and IL-8, were observed in ex vivo serum collected from CHB carriers with PC mutant.ConclusionHBV sequence variation leads to differences in HBV protein production (HBeAg) and viral replication in addition to altered host innate antiviral restriction factor (APOBEC3) and cytokine/chemokine expression.

Highlights

  • The hepatitis B virus (HBV) is a significant global pathogen with ∼257 million chronic HBV (CHB) carriers worldwide (WHO, 2017)

  • We evaluated whether APOBEC3 activity and expression is altered by X/basal core promoter (BCP)/PC variants as a mechanism that increased risk of end-stage liver disease (i.e, hepatocellular carcinoma (HCC) and cirrhosis) in CHB carriers harboring these mutants

  • We evaluated in vitro the functional properties of two clinically important genetic variants of HBV associated with HCC, the G1896A and A1762T/G1764A mutations

Read more

Summary

Introduction

The hepatitis B virus (HBV) is a significant global pathogen with ∼257 million chronic HBV (CHB) carriers worldwide (WHO, 2017). CHB can lead to cirrhosis, liver failure, and hepatocellular carcinoma (HCC). HBV-related oncogenesis is complex and is influenced by viral characteristics such as genetic variants within the X/basal core promoter (BCP)/pre-core (PC) region and integration into the host chromosomes contributing to genomic instability and hepatocarcinogenesis. Chronic hepatitis B virus (HBV) infection is the leading cause of hepatocellular carcinoma (HCC) world-wide. HBV variants, the G1896A precore (PC) and A1762T/G1764A basal core promoter (BCP) mutations, are established risk factors for cirrhosis and HCC, but the molecular biological basis is unclear. We hypothesized that these variants result in differential HBV replication, APOBEC3 family expression, and cytokine/chemokine expression

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call